In this way, the frequency of PD-1+ CD4+ T cells, PD-1+ CD8+ T cells, PD-L1+ interleukin (IL)-10+ CD14+ cells, and PD-L1+ IL-10+ CD19+ cells in MS patients were found to be notably higher in the remitting phase compared to the relapsing phase [32]. This evidence concerns the gene CD8A and myeloid sarcoma.